Table 2.
The effect of dexmedetomidine on serum glucose levels and body weight (n=20, mean ± SEM).
| Group | Serum glucose (mmol/l) | Body weight (g) | ||||
|---|---|---|---|---|---|---|
| 1 d | 35 d | 70 d | 1 d | 35 d | 70 d | |
| C | 5.42 ± 0.25 | 5.40 ± 0.23 | 5.51 ± 0.37 | 150.12 ± 3.10 | 218.63 ± 4.23* | 273.32 ± 8.58*# |
| DPN | 5.50 ± 0.21 | 21.51 ± 0.81*& | 22.95 ± 1.06*& | 149.10 ± 2.87 | 213.32 ± 5.61* | 176.12 ± 5.74*#& |
| DEX | 5.43 ± 0.19 | 22.28 ± 1.26*& | 22.09 ± 0.76*& | 152.12 ± 2.98 | 214.23 ± 7.73* | 180.13 ± 7.53*#& |
| YOH | 5.44 ± 0.25 | 21.80 ± 0.87*& | 21.54 ± 1.20*& | 149.94 ± 3.01 | 216.19 ± 8.57* | 187.24 ± 6.37*#& |
C, control; DPN, diabetic peripheral neuropathy; DEX, dexmedetomidine; YOH, yohimbine.
*p < 0.05 compared with the 1 d at the same group, #p < 0.05 compared with the 35 d at the same group, &p < 0.05 compared with the C group on the same day.